Hims & Hers Health (NYSE:HIMS) CFO Oluyemi Okupe Sells 55,383 Shares

Hims & Hers Health, Inc. (NYSE:HIMS) CFO Oluyemi Okupe sold 55,383 shares of the business’s stock in a transaction that occurred on Thursday, June 18th. The shares were sold at an average price of $35.09, for a total value of $1,943,389.47. Following the completion of the sale, the chief financial officer owned 228,938 shares of the company’s stock, valued at $8,033,434.42. The trade was a 19.48% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Oluyemi Okupe also recently made the following trade(s):

• On Monday, August 17th, Oluyemi Okupe sold 9,388 shares of Hims & Hers Health stock. The shares were sold at an average price of $27.89, for a total value of $261,831.32.
• On Monday, July 6th, Oluyemi Okupe sold 7,163 shares of Hims & Hers Health stock. The stock was sold at an average price of $36.49, for a total transaction of $261,377.87.
• On Monday, June 22nd, Oluyemi Okupe sold 18,197 shares of Hims & Hers Health stock. The shares were sold at an average price of $34.03, for a total transaction of $619,243.91.

Hims & Hers Health Trading Down 4.1%

Shares of NYSE:HIMS traded down $1.19 during midday trading on Tuesday, hitting $27.43. 7,895,463 shares of the stock traded hands, compared to its average volume of 26,328,367. The company has a quick ratio of 0.87, a current ratio of 0.93 and a debt-to-equity ratio of 4.21. The business’s 50 day moving average is $32.14 and its two-hundred day moving average is $26.05. The stock has a market capitalization of $6.40 billion, a PE ratio of -43.53 and a beta of 2.40. Hims & Hers Health, Inc. has a one year low of $13.74 and a one year high of $65.30.

Hims & Hers Health (NYSE:HIMS) last posted its earnings results on Monday, August 10th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by ($0.32). The business had revenue of $753.21 million for the quarter, compared to analysts’ expectations of $698.90 million. Hims & Hers Health had a negative net margin of 5.51% and a negative return on equity of 6.51%. Hims & Hers Health’s quarterly revenue was up 38.2% on a year-over-year basis. During the same period last year, the firm posted $0.17 earnings per share. As a group, research analysts forecast that Hims & Hers Health, Inc. will post -0.05 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the business. Vanguard Group Inc. increased its position in Hims & Hers Health by 7.2% during the 4th quarter. Vanguard Group Inc. now owns 20,925,666 shares of the company’s stock valued at $679,456,000 after buying an additional 1,407,651 shares in the last quarter. Munich Reinsurance Co Stock Corp in Munich bought a new stake in Hims & Hers Health in the fourth quarter worth $11,187,000. Cunning Capital Partners LP bought a new stake in Hims & Hers Health in the fourth quarter worth $1,110,000. Norges Bank purchased a new stake in shares of Hims & Hers Health in the fourth quarter worth $62,153,000. Finally, Virtu Financial LLC bought a new position in shares of Hims & Hers Health during the fourth quarter valued at $1,937,000. 63.52% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on HIMS shares. Zacks Research raised shares of Hims & Hers Health from a “strong sell” rating to a “hold” rating in a research note on Monday, July 13th. Bank of America raised their price objective on shares of Hims & Hers Health from $30.00 to $32.00 and gave the stock a “neutral” rating in a report on Tuesday, August 11th. Morgan Stanley lifted their price objective on Hims & Hers Health from $21.00 to $28.00 and gave the company an “equal weight” rating in a research report on Tuesday, August 11th. Needham & Company LLC upped their target price on Hims & Hers Health from $35.00 to $42.00 and gave the stock a “buy” rating in a report on Tuesday, August 11th. Finally, Weiss Ratings reissued a “sell (d)” rating on shares of Hims & Hers Health in a research report on Friday, August 7th. Four analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Hims & Hers Health has a consensus rating of “Hold” and a consensus price target of $32.43.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.